Description
Methyl Ergonovine Maleate Tablet
Methyl Ergonovine Maleate Tablets (0.2 mg)
Methylergometrine Maleate USP / BP / IP — Oxytocic Uterotoner
Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale supplier of advanced gynecology, obstetrics, and maternal health therapeutics. We manufacture ultra-high-purity, kinetically stable Methyl Ergonovine Maleate Tablets inside our WHO–GMP certified, high-precision solid dosage manufacturing installations. This critical “Ergot Alkaloid Oxytocic Agent” serves as a high-volume strategic export to maternity hospital networks, emergency medical pipelines, national health ministry procurement tenders, and international B2B pharmaceutical marketplaces across Africa, the CIS region, LATAM, and Southeast Asia.
Product Overview
This formulation operates as an “Active Myometrial Constrictor.” It ensures patient safety in the immediate postpartum period by chemically forcing sustained uterine contraction, physically sealing off open vascular channels at the placental detachment site to halt life-threatening maternal bleeding.
Mechanism 1 (Alpha-Adrenergic & Serotonergic Activation): Methyl Ergonovine physically acts as a partial agonist across Alpha-1 Adrenergic, Serotonergic ($5\text{-HT}_{2}$), and Dopaminergic receptors located on uterine smooth muscle cells (myometrium).
Mechanism 2 (Tetanic Myometrial Contraction): This complex receptor binding chemically stimulates an influx of extracellular calcium ions into the cell cytoplasm. This induces a state of sustained, high-frequency tetanic uterine contraction, rapidly reducing overall uterine volume.
Mechanism 3 (Vascular Compression Hemostasis): The violent physical contraction of the surrounding uterine muscle fibers directly compresses the spiral arteries and dilated venous sinuses within the uterine wall. This physical constriction establishes immediate mechanical hemostasis (clotting) without interfering with the blood’s systemic coagulation cascade.
Product Composition & Calibration Strength
We manufacture this critical emergency therapeutic in the globally accepted standard micro-dose strength optimized for postpartum routine oral management.
| Active Ingredient Common Name | Compendial Monograph | Standard Strength | Primary Clinical Target |
| Methyl Ergonovine Maleate (Methylergometrine Maleate) | USP / BP / IP | 0.2 mg (200 mcg) | The Uterotoner Matrix: Administered orally following initial IV/IM stabilization to maintain uterine tone and prevent bleeding recurrence. |
| Excipients | Pharma Grade | Lactose, Starch, Povidone binders | The Delivery Scaffold: Engineered for rapid physical disintegration and quick mucosal absorption. |
Technical & Logistics Specifications
HS Code: 3004.49.10 (Medicaments containing alkaloids or derivatives thereof / Ergot alkaloids or derivatives)
CAS Number: 57432-61-8 (Methyl Ergonovine Maleate)
Dosage Form: Oral Solid Tablet
Packaging Configurations: 10 or 14 Tablets per Blister packed exclusively in heavy-duty, high-barrier Alu-Alu (Cold-Form Foil) or deep-amber PVC/PVDC strips. Methyl Ergonovine is highly physically unstable when exposed to light and ambient oxygen; our premium tropicalized opaque packaging completely isolates the core molecule, guaranteeing a 24-to-36-month shelf life under challenging Zone IVb export conditions.
Manufacturing Authority & Compliance
Micro-Dose Content Uniformity: Because Methyl Ergonovine is compressed at an exceptionally low microgram dose (0.2 mg) relative to the total tablet weight, we deploy Automated Multi-Stage Geometric Solid Blenders. This physically guarantees absolute chemical content uniformity across every tablet to prevent dangerous under-dosing or toxic spikes.
Photo-Stability Environment Controls: The active crystalline structures of ergot compounds physically degrade into inactive chemical forms when exposed to specific ambient light spectra. Our processing suites utilize UV-Filtered Isolated Lighting Enclosures throughout the granulating, tableting, and final foil blister-sealing phases to preserve molecular potency.
Validated Disintegration Performance: Every production batch physically undergoes Automated Disintegration Profiling, chemically ensuring that the tablet breaks down inside the gastrointestinal tract in under 10 minutes to deliver rapid therapeutic onset during a maternal emergency.
Primary Indications
Obstetrics: Routine prevention and management of Postpartum Hemorrhage (PPH) and postabortal hemorrhage associated with uterine atony (loss of muscle tone).
Gynecology: Adjuvant management of subinvolution of the uterus (delayed return to normal size) and secondary postpartum bleeding.
Usage Instructions
The Follow-Up Window: Oral therapy is physically optimized when utilized as a follow-up regimen to maintain uterine contraction after initial emergency stabilization has been accomplished via intramuscular or intravenous oxytocic injection.
Administration Matrix: Take one 0.2 mg tablet physically by mouth 3 to 4 times daily for a maximum duration of 1 week (7 days) post-delivery to ensure the uterine cavity safely collapses to its baseline anatomical volume.
The Blood Pressure Directive: Prior to administering the tablet, clinical staff must physically verify the patient’s blood pressure. Methyl Ergonovine chemically causes mild-to-moderate peripheral vasoconstriction, which can physically aggravate hypertensive states.
Safety Warning: HIGH-ALERT OBSTETRIC EMERGENCY THERAPEUTIC. For Professional Medical Supervision Only. Hypertension Hazard: May cause sudden, severe Vasoconstriction and Hypertensive Spikes; monitor blood pressure closely during administration. Ergotism Note: Do not exceed the maximum 7-day dosing threshold to physically prevent signs of ergotism (peripheral numbness, cold extremities). Absolute Contraindications: NEVER ADMINISTER FOR THE INDUCTION OR AUGMENTATION OF ACTIVE LABOR. Direct contraction can induce fetal asphyxia and uterine rupture. Do not use in patients presenting with pre-eclampsia, eclampsia, severe uncontrolled hypertension, peripheral vascular disease, or known hypersensitivity to ergot alkaloids.
Global CDMO Services & Wholesale Supply Chain
Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and high-volume bulk private-label export supply for generic Methyl Ergonovine Maleate Tablets. Whether you are executing a procurement contract for an African National Maternal Health Tender, supplying an emergency obstetric infrastructure network in the CIS region, or maintaining active inventory listings on an international digital B2B Pharmaceutical Marketplace across Southeast Asia or LATAM, we deliver all required compliance documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.
Commercial & Bulk Procurement Inquiries:
Corporate Head Office: Mumbai, Maharashtra, India
Primary Manufacturing Base: Boisar, Maharashtra, India
WhatsApp / Direct Call: +91 7710003340
Corporate Email: info@healthyinc.co.in
